Can Fite Biopharma Ltd (CANF)
$3.01
+0.14
(+4.88%)▲
Live
Performance
- $2.73$3.12$3.01
9.3%
Downside
Day's Volatility :12.5%
Upside
3.53%
- $1.81$4.69$3.01
39.87%
Downside
52 Weeks Volatility :61.41%
Upside
35.82%
Returns
| Period | Can Fite Biopharma Ltd | Index (Russel 2000) |
|---|---|---|
3 Months | -24.67% | 0.0% |
6 Months | 44.95% | 0.0% |
1 Year | 49.48% | 0.0% |
3 Years | -81.72% | -23.0% |
Highlights
Market Capitalization | 17.5M |
Book Value | $0.00 |
Earnings Per Share (EPS) | -2.6 |
PEG Ratio | 0.0 |
Wall Street Target Price | 13.33 |
Profit Margin | 0.0% |
Operating Margin TTM | -1295.57% |
Return On Assets TTM | -57.46% |
Return On Equity TTM | -157.62% |
Revenue TTM | 667.0K |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -19.400000000000002% |
Gross Profit TTM | 810.0K |
EBITDA | -7.8M |
Diluted Eps TTM | -2.6 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.39 |
EPS Estimate Next Year | -0.73 |
EPS Estimate Current Quarter | -0.44 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
Analyst Forecast
What analysts predicted
Upside of 342.86%
Technicals Summary
Sell
Neutral
Buy
Can Fite Biopharma Ltd is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Can Fite Biopharma Ltd | 40.69% | 44.95% | 49.48% | -81.72% | -87.84% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Can Fite Biopharma Ltd | NA | NA | 0.0 | -1.39 | -1.58 | -0.57 | NA | 0.0 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Can Fite Biopharma Ltd | NA | $17.5M | -87.84% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Can Fite Biopharma Ltd
Decreasing Revenue
Revenue is down for the last 9 quarters, 205.0K → 158.0K (in $), with an average decrease of 3.0% per quarter
Decreasing Net Profit
Netprofit is down for the last 4 quarters, -1.67M → -1.97M (in $), with an average decrease of 5.9% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 43.6%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 126.5%
Company Information
can fite biopharma (canfy) is a biotechnology company based out of 10 bareket street, פ"ת, israel.
Organization | Can Fite Biopharma Ltd |
Employees | 8 |
CEO | Dr. Pnina Fishman Ph.D. |
Industry | Health Technology |
Discover More
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$3.01
+4.88%
Invesco Bulletshares 2025 Hi
$3.01
+4.88%
Schwab International Dividend Equity Etf
$3.01
+4.88%
Blockchain Coinvestors Acquisition Corp.
$3.01
+4.88%
Allgiant Travel Company
$3.01
+4.88%
Rogers Corp
$3.01
+4.88%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$3.01
+4.88%
Iheartmedia
$3.01
+4.88%
Lightpath Technologies Inc
$3.01
+4.88%